Top Glove Corporation (7113) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Top Glove Corporation stock MYR 0.29, price MYR 0.97, upside -70.1%, quality 64 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 24, 2026.
How to read this chart
60‑month range 0.5450 MYR – 4.23 MYR · fair‑value band 0.2000 MYR – 0.4000 MYR · the 0.9700 MYR price screens above the 0.2900 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Oct 24, 2026.
Follow Top Glove in your weekly email
Every Wednesday you see whether Top Glove is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Top Glove Corporation Bhd., an investment holding company, engages in the manufacture, trade, and sale of gloves in Malaysia, Thailand, the People's Republic of China, and internationally.
Show moreShow less
It offers nitrile, latex, surgical, rubber, examination, medical, and vinyl gloves; concentrate and synthetic latex, formers, chemicals and chemical compounds, rubber dental dams, exercise bands, condoms, and rubber related products; packaging materials, boxes, and cartons; and disposable and medical face masks, engineering parts and rubber glove machinery, functional fillers, healthcare products, and home care and personal care products.
The company also provides property investment and consultancy services, and electrical engineering works; clinical and specialist medical services; analytical, medical related consultancy, emergency medical, advisory, accommodation, management and trading, and value added services; financial and treasury services; management services in plantation sector; processing of plantation produce; and industrial forest plantation services, as well as forestry and industry services.
In addition, it trades in healthcare related products; distributes medical devices and products; operates as a special purpose vehicle solely for issuance of Perpetual Sukuk; organizes in-house trainings and public trainings/programs; and establishes and maintains fitness related business, including healthcare, slimming centers, gymnasiums, and other related activities.
Further, it generates and supplies energy and electricity using biomass technology; and offers e-commerce services for glove trading and other healthcare products.
Additionally, the company provides gamma irradiation services for sterilization of gloves and medical devices; acts as an agent in the sale of various goods; wholesales pharmaceutical goods; and buys and sells real estate.
Top Glove Corporation Bhd. was founded in 1991 and is headquartered in Shah Alam, Malaysia.
Stock analysis
Top Glove Corporation (7113) currently trades at 0.9700 MYR, while our model-based Fair Value estimate is 0.2900 MYR, 70.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 0.3300 MYR per share, and 1 of the 26 models we run sit above the 0.9700 MYR price.
Bear case: the Dividend Discount group reads lowest at 0.0700 MYR, and 25 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.2000 MYR (bear) to 0.4000 MYR (bull), the price of 0.9700 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Top Glove Corporation reported revenue of 3.5B MYR in FY2025 versus 16.4B MYR in FY2021, a compound −32.0%/yr. Reported net income was 128M MYR in FY2025, compounding −64.1%/yr from FY2021.
Key figures
Market cap 7.8B MYR (≈ $1.9B) Small · P/E ratio 48.5 · P/S ratio 2.01 · EPS (TTM) 0.0200 MYR · Dividend yield 0.5% · Net margin 4.8% · Return on equity 3.8% · Return on assets (EBIT) 19.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 78% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −70%, 7113 screens richer than that median.
Fair Value models
Bear0.2000 MYRFair Value 0.2900 MYRBull0.4000 MYR
Price 0.9700 MYR · Upside -70.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0150 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+38.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.6%
Start year 2020 (pandemic). Over 10 years: +3.3% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−40.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−40.8%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−40.8% vs −8.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 3%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +31.3% a year for the price and +8.8% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 187 stocks
Beats the industry median on 6/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside−70.1% · Bottom 25%
Profitability
Return on equity (12 months)3.8% · Below median
Return on assets2.1% · Below median
Net margin (12 months)4.8% · Below median
Operating margin (12 months)13.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)31.9% · Top 25%
Dividend yield (12 months)0.5% · Bottom 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)48.5× · Priciest 25%
P/B1.64× · Cheaper than median
P/S (12 months)2.01× · Cheaper than median
Price / free cash flow53.7× · Priciest 25%
EV/EBITDA18.6× · Pricier than median
PEG0.46× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)100· sector 40
PAST (return on equity)15· sector 28
HEALTH (low debt)92· sector 96
DIVIDEND (yield)10· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Top Glove Corporation (7113) overvalued or undervalued?
As of Oct 24, 2026, our model estimates a fair value of 0.2900 MYR versus a price of 0.9700 MYR, about −70% upside (overvalued).
What is the fair value of 7113?
Our model-based fair value for Top Glove Corporation is 0.2900 MYR (as of Oct 24, 2026), built from audited fundamentals. The current price: 0.9700 MYR.
What is the quality score of 7113?
Top Glove Corporation has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Top Glove Corporation (7113)?
Our model-based price target is the fair value of 0.2900 MYR (as of Oct 24, 2026) from 26 valuation models. Cautious scenario 0.2000 MYR, optimistic scenario 0.4000 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Top Glove Corporation stock forecast for 2026?
Our models put fair value at 0.2900 MYR, about −70% upside versus a price of 0.9700 MYR (overvalued). Cautious scenario 0.2000 MYR, optimistic scenario 0.4000 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Top Glove Corporation (7113)?
Top Glove Corporation reported trailing-twelve-month revenue of about 3.9B MYR (latest available figure, as of Oct 24, 2026).
Does Top Glove Corporation pay a dividend?
Top Glove Corporation currently shows a dividend yield of 0.52% relative to its recent price (as of Oct 24, 2026).
What growth is priced into Top Glove Corporation (7113)?
For today's price to be fair in a discounted-cash-flow model, Top Glove Corporation would have to grow free cash flow by +33.9 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.6 % per year. As of Oct 24, 2026.
What discount rate (WACC) does the fair value of 7113 use?
Our models discount Top Glove Corporation at 11.1 %: a base by market capitalisation (small), damped by beta 0.46, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Top Glove Corporation that is +33.9 % per year a year over ten years, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Top Glove Corporation (7113) delivered so far?
Over the past 5 years revenue at Top Glove Corporation grew -13.6 % a year. The price currently implies +33.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Top Glove Corporation (7113) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Top Glove Corporation (+33.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Top Glove Corporation (7113)?
The free-cash-flow yield on the price is 1.86 %: that much free cash flow Top Glove Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Top Glove Corporation (7113)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Top Glove Corporation it is 0.2900 MYR per share (as of Oct 24, 2026), against a price of 0.9700 MYR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Top Glove Corporation stock overvalued or undervalued in 2026?
As of Oct 24, 2026, 7113 trades above its calculated fair value: price 0.9700 MYR, fair value 0.2900 MYR, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7113?
No. The price is what the market pays today (0.9700 MYR); the fair value is what the company's own numbers justify (0.2900 MYR). For Top Glove Corporation the two are 0.6800 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Top Glove Corporation worth?
The market values Top Glove Corporation at about 7.8B MYR (market capitalisation, as of Oct 24, 2026). Per share that is 0.9700 MYR; our models calculate a fair value of 0.2900 MYR per share.
What do the bullish and bearish scenarios say about 7113?
Our models span a range for Top Glove Corporation: cautious scenario 0.2000 MYR, base 0.2900 MYR, optimistic 0.4000 MYR per share (as of Oct 24, 2026, price 0.9700 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7113?
Top Glove Corporation trades at a price-to-earnings ratio of 48.5 (as of Oct 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.2900 MYR is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 71.3 (reported for FY2025: 60.6). Other multiples: PEG 0.5, P/B 1.6, P/S 2.0, EV/EBITDA 18.6.
What is the PEG ratio of 7113?
The PEG ratio of Top Glove Corporation is 0.46 (P/E divided by earnings growth, as of Oct 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Top Glove Corporation (7113)?
Balance-sheet figures for Top Glove Corporation (as of Oct 24, 2026): return on equity 3.8%, debt of 0.17 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 7113 from its 52-week high?
Top Glove Corporation trades at 0.9700 MYR, at its 52-week high of 0.9700 MYR and 78% above the low of 0.5450 MYR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2900 MYR is for.
Which stocks are comparable to Top Glove Corporation?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Top Glove Corporation stock attractive at the current price?
The data as of Oct 24, 2026: price 0.9700 MYR, calculated fair value 0.2900 MYR (−70%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7113 calculated?
We run Top Glove Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2900 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Top Glove Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Top Glove Corporation (7113)?
The closing price on Oct 28, 2026 was 0.9700 MYR. Our model-based fair value is 0.2900 MYR, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Top Glove Corporation right now?
The price sits above even our optimistic bull case (0.4000 MYR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (0.2000 MYR to 0.4000 MYR) leaves room in how you read the outcome.
Key figures of Top Glove Corporation
How large is the market capitalisation of Top Glove Corporation (7113)?
The market capitalisation of Top Glove Corporation is 7.8B MYR (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Top Glove Corporation (7113)?
The price-to-sales ratio of Top Glove Corporation is 2.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Top Glove Corporation (7113)?
Earnings per share at Top Glove Corporation are 0.0200 MYR (price ÷ EPS = P/E 48.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Top Glove Corporation (7113)?
The dividend yield of Top Glove Corporation is 0.5% (payout 29.4%, on adjusted earnings, reported 25.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Top Glove Corporation (7113)?
The net margin of Top Glove Corporation is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Top Glove Corporation (7113)?
The return on equity (ROE) of Top Glove Corporation is 3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Top Glove Corporation (7113)?
On an EBIT basis the return on assets of Top Glove Corporation is 19.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Top Glove Corporation (7113)?
The operating margin of Top Glove Corporation is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Top Glove Corporation (7113)?
Revenue at Top Glove Corporation is growing +31.9% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Top Glove Corporation (7113)?
Earnings per share at Top Glove Corporation are growing +135% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Top Glove Corporation (7113) carry?
The net debt of Top Glove Corporation is 551M MYR (fiscal year 2025, ≈ 3.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Top Glove Corporation in the live analysis
One click puts Top Glove Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 24, 2026